Article3 Biotech2019
Microbial diversity of a Himalayan forest and characterization of rare actinomycetes for antimicrobial compounds.
Article in 3 Biotech, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Antibiotic Resistance Crisis: From Bacterial Bioprospecting to Artificial Intelligence.Environmental microbiology reports · 2025Review
- Antimicrobial potential of actinomycetes from high altitude Nepalese soils.Scientific reports · 2025Article
- Investigation of anti-microbial and cytotoxic potential of Streptomyces werraensis GRS9 derived from the sediments of river Ganga.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Identifying Potential Natural Antibiotics from Unani Formulas through Machine Learning Approaches.Antibiotics (Basel, Switzerland) · 2024Article
- Genomic and physiological characterization of Kitasatospora sp. nov., an actinobacterium with potential for biotechnological application isolated from Cerrado soil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- Biodiversity and Bioactive Potential of Actinomycetes from Unexplored High Altitude Regions of Kargil, India.Indian journal of microbiology · 2024Article
- Himalayan Microbiomes for Agro-environmental Sustainability: Current Perspectives and Future Challenges.Microbial ecology · 2022Review
- Antimicrobial Potential ofAdvances in pharmacological and pharmaceutical sciences · 2022Article
- Antimicrobial and antifungal activity of soil actinomycetes isolated from coal mine sites.Saudi journal of biological sciences · 2021Article
- Advances in actinomycete research: an ActinoBase review of 2019.Microbiology (Reading, England) · 2020Review
- Microbial Ecology from the Himalayan Cryosphere Perspective.Microorganisms · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The slow pace of discovery of new effective drugs against multi-drug resistant pathogens and largely unsuccessful combinatorial chemistry has resulted in shifting the focus back to natural products as sources of lead molecules for antimicrobial drugs, mainly due to their structural diversity. Investigation of under-explored habitats for potentially novel microorganisms provides for wider chemodiversity. In this study, four actinomycetes, namely UK-274, UK-281, UK-282 and UK-285, which showed broad-spectrum antibacterial and antifungal activities, were isolated from Timli forest range of the biodiversity-rich Himalayan region. 16S rRNA gene sequence analysis showed that the nearest neighbours of the isolates were
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.